Autor(es):
Grando, Aline Vitali ; Ferreira, Paulo Roberto Abrão ; Pessôa, Mário Guimarães ; Mazo, Daniel Ferraz de Campos ; Brandão-Mello, Carlos Eduardo ; Reuter, Tânia ; Martinelli, Ana de Lourdes Candolo ; Gonzalez, Mário Peribanez ; Nastri, Ana Catharina Seixas-Santos ; Campos, Aléia Faustina ; Lopes, Max Igor Banks Ferreira ; Brito, José David Urbaez ; Mendes-Corrêa, Maria Cássia
Data: 2017
Origem: Oasisbr
Assunto(s): Hepatitis C; Chronic hepatitis C; Coinfection HCV-HIV; Interferons; Ribavirin; HCV genotypes
Descrição
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p
